The ecology of cancer from an evolutionary game theory perspective

The accumulation of somatic mutations, to which the cellular genome is permanently exposed, often leads to cancer. Analysis of any tumour shows that, besides the malignant cells, one finds other ‘supporting’ cells such as fibroblasts, immune cells of various types and even blood vessels. Together, these cells generate the microenvironment that enables the malignant cell population to grow and ultimately lead to disease. Therefore, understanding the dynamics of tumour growth and response to therapy is incomplete unless the interactions between the malignant cells and normal cells are investigated in the environment in which they take place. The complex interactions between cells in such an ecosystem result from the exchange of information in the form of cytokines- and adhesion-dependent interactions. Such processes impose costs and benefits to the participating cells that may be conveniently recast in the form of a game pay-off matrix. As a result, tumour progression and dynamics can be described in terms of evolutionary game theory (EGT), which provides a convenient framework in which to capture the frequency-dependent nature of ecosystem dynamics. Here, we provide a tutorial review of the central aspects of EGT, establishing a relation with the problem of cancer. Along the way, we also digress on fitness and of ways to compute it. Subsequently, we show how EGT can be applied to the study of the various manifestations and dynamics of multiple myeloma bone disease and its preceding condition known as monoclonal gammopathy of undetermined significance. We translate the complex biochemical signals into costs and benefits of different cell types, thus defining a game pay-off matrix. Then we use the well-known properties of the EGT equations to reduce the number of core parameters that characterize disease evolution. Finally, we provide an interpretation of these core parameters in terms of what their function is in the ecosystem we are describing and generate predictions on the type and timing of interventions that can alter the natural history of these two conditions.

[1]  Josef Hofbauer,et al.  Evolutionary Games and Population Dynamics , 1998 .

[2]  G. Roodman Pathogenesis of myeloma bone disease , 2009, Journal of cellular biochemistry.

[3]  M. Elmantaser,et al.  Secondary osteoporosis. , 2009, Endocrine development.

[4]  T. Kunkel,et al.  DNA replication fidelity. , 1992, The Journal of biological chemistry.

[5]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[6]  J M Smith,et al.  Evolution and the theory of games , 1976 .

[7]  B. Barlogie,et al.  Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. , 2008, Bone.

[8]  Gordon My,et al.  Routes to repopulation--a unification of the stochastic model and separation of stem-cell subpopulations. , 1994 .

[9]  E. Terpos,et al.  New insights into the pathophysiology and management of bone disease in multiple myeloma , 2003, British journal of haematology.

[10]  F. C. Santos,et al.  Risk of collective failure provides an escape from the tragedy of the commons , 2011, Proceedings of the National Academy of Sciences.

[11]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.

[12]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[13]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[14]  Lucio Luzzatto,et al.  The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. , 2010, Mutation research.

[15]  X. Mariette,et al.  The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression , 2004, Leukemia & lymphoma.

[16]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[17]  A. Traulsen,et al.  Explaining the in vitro and in vivo differences in leukemia therapy , 2011, Cell cycle.

[18]  Francisco C. Santos,et al.  A bottom-up institutional approach to cooperative governance of risky commons , 2013 .

[19]  F. C. Santos,et al.  Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells , 2009, British Journal of Cancer.

[20]  M. Dimopoulos,et al.  Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.

[21]  Arne Traulsen,et al.  (A)Symmetric Stem Cell Replication and Cancer , 2007, PLoS Comput. Biol..

[22]  K. Moriyama,et al.  Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. , 2004, Blood.

[23]  A. Traulsen,et al.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells , 2009, Haematologica.

[24]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[25]  J. Epstein,et al.  Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.

[26]  Bart Barlogie,et al.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.

[27]  C. Dinarello Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. , 2009, Mayo Clinic proceedings.

[28]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[29]  G. Roodman,et al.  Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.

[30]  J. Berenson Bone disease in myeloma , 2001, Current treatment options in oncology.

[31]  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.

[32]  Jorge M. Pacheco,et al.  Compartmental Architecture and Dynamics of Hematopoiesis , 2007, PloS one.

[33]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[34]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[36]  Lucio Luzzatto,et al.  A quantitative measurement of the human somatic mutation rate. , 2005, Cancer research.

[37]  D. Jelinek,et al.  Mechanisms of myeloma cell growth control. , 1999, Hematology/oncology clinics of North America.

[38]  T. Weber,et al.  SECONDARY OSTEOPOROSIS : Diagnostic Considerations , 1998 .

[39]  L. Melton,et al.  Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. , 2011, Blood.

[40]  Arne Traulsen,et al.  Somatic mutations and the hierarchy of hematopoiesis , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[41]  A. Traulsen,et al.  Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse , 2008 .

[42]  R. Fonseca,et al.  Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. , 2012, Blood.

[43]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[44]  G. Roodman,et al.  Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease , 2001 .

[45]  A. Traulsen,et al.  Reproductive fitness advantage of BCR-ABL expressing leukemia cells. , 2010, Cancer letters.

[46]  T. Kunkel DNA Replication Fidelity* , 2004, Journal of Biological Chemistry.

[47]  Jorge M Pacheco,et al.  Acquired hematopoietic stem-cell disorders and mammalian size. , 2007, Blood.

[48]  L. Imhof,et al.  Stochasticity and evolutionary stability. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.

[49]  J. Shaughnessy,et al.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.

[50]  Peter Guttorp,et al.  Evidence that hematopoiesis may be a stochastic process in vivo , 1996, Nature Medicine.

[51]  O. Stephens,et al.  Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. , 2008, Blood.

[52]  Toshio Matsumoto,et al.  Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma , 2004, British journal of haematology.

[53]  N. Raje,et al.  Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma , 2011, Clinical Cancer Research.

[54]  G. Roodman Erratum to ?Pathogenesis of myeloma bone disease? 6Blood Cells Mol. Dis. 32 (2004) 290?2929 , 2004 .

[55]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[56]  G. Roodman,et al.  Role of the Bone Marrow Microenvironment in Multiple Myeloma , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[58]  Natalia L. Komarova,et al.  Computational Biology of Cancer: Lecture Notes and Mathematical Modeling , 2005 .

[59]  N. Komarova,et al.  Symmetric vs. Asymmetric Stem Cell Divisions: An Adaptation against Cancer? , 2013, PloS one.

[60]  Wei Zhang,et al.  Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. , 2014, Blood.

[61]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[62]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.